# VivaVision Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/vivavision-biotech

- Industry: Healthcare Specialists
- Headquarters: Wenzhou, China
- Website: www.vivavisionbio.com
- Total disclosed funding: $80M
- Latest round: Series D (May 5, 2023)
- Investors on record: 19

## About

Based in Shanghai, China, and founded in 2016, VivaVision Biotech, Inc. is a biopharmaceutical company that focused on the R&D of new drugs for ophthalmic diseases and dermal inflammatory diseases. The company also established a branch office in Jiaxing. In July 2025, VivaVision Biotech, Inc. raised CNY 140 million in series D2+ funding from new investor Hunan Energy Investment Group. Since 2020, the company has had clinical testing in the USA and China. The CEO of the company Dr. Shen Wang, was the founder and CEO of Kanion USA. The company developed new drugs to treat ophthalmic diseases and dermal inflammatory diseases. The pipeline VVN001 can be used for treating dry eye diseases, The pipeline VVN460 can be used for treating plaque psoriasis. The pipeline VVN539 can be used for treating glaucoma. The pipeline vvn001 is in the clinical stage, and other ocular surfaces and fundus treatment products are in different stages of development.

## Funding rounds

- Series D, May 5, 2023, $14M — V-Capital, Chifortune Venture Capital, Sunbow Capital, VVB Capital
- Series D, Apr 19, 2021, $46M — Hong Shan, GTJA Investment Group, Cenova Ventures, FengHe Fund Management, Changrong Capital, Beida Fund, Viva Ventures Biotech, Zhangjiang Torch Investment, Shenzhen Zhongjince Investment Co., Ltd
- Series C, Sep 26, 2019, $9.1M — Changrong Capital, Beida Fund, Ming Bioventures, Viva Ventures Biotech, Yingqi Investment, Donghan International
- Series B, Jul 12, 2018, $7.5M — Lapam Capital
- Series A, May 8, 2017 — JMCR Family Office, Tao Capital, Viva Ventures Biotech
- Angel, Nov 16, 2016, $2.4M — Viva Ventures Biotech

## Investors

- Viva Ventures Biotech (https://capitalatlas.ai/funds/viva-ventures-biotech) — Angel, Series A, Series C, Series D
- JMCR Family Office — Series A
- Tao Capital (https://capitalatlas.ai/funds/tao-capital) — Series A
- Lapam Capital (https://capitalatlas.ai/funds/lapam-capital) — Series B
- Changrong Capital — Series C, Series D
- Beida Fund (https://capitalatlas.ai/funds/beida-fund) — Series C, Series D
- Ming Bioventures (https://capitalatlas.ai/funds/ming-bioventures) — Series C
- Yingqi Investment — Series C
- Donghan International — Series C
- Hong Shan — Series D
- GTJA Investment Group (https://capitalatlas.ai/funds/gtja-investment-group) — Series D
- Cenova Ventures (https://capitalatlas.ai/funds/cenova-ventures) — Series D
- FengHe Fund Management (https://capitalatlas.ai/funds/fenghe-fund-management) — Series D
- Zhangjiang Torch Investment (https://capitalatlas.ai/funds/zhangjiang-torch-investment) — Series D
- Shenzhen Zhongjince Investment Co., Ltd — Series D
- V-Capital (https://capitalatlas.ai/funds/v-capital) — Series D
- Chifortune Venture Capital (https://capitalatlas.ai/funds/chifortune-venture-capital) — Series D
- Sunbow Capital (https://capitalatlas.ai/funds/sunbow-capital) — Series D
- VVB Capital — Series D